肝硬化患者肝脏中的 PKD1 突变克隆可抑制脂肪性肝炎,但不会诱发癌症

IF 27.7 1区 生物学 Q1 CELL BIOLOGY
Min Zhu, Yunguan Wang, Tianshi Lu, Jason Guo, Lin Li, Meng-Hsiung Hsieh, Purva Gopal, Yi Han, Naoto Fujiwara, Darren P. Wallace, Alan S.L. Yu, Xiangyi Fang, Crystal Ransom, Sara Verschleisser, David Hsiehchen, Yujin Hoshida, Amit G. Singal, Adam Yopp, Tao Wang, Hao Zhu
{"title":"肝硬化患者肝脏中的 PKD1 突变克隆可抑制脂肪性肝炎,但不会诱发癌症","authors":"Min Zhu, Yunguan Wang, Tianshi Lu, Jason Guo, Lin Li, Meng-Hsiung Hsieh, Purva Gopal, Yi Han, Naoto Fujiwara, Darren P. Wallace, Alan S.L. Yu, Xiangyi Fang, Crystal Ransom, Sara Verschleisser, David Hsiehchen, Yujin Hoshida, Amit G. Singal, Adam Yopp, Tao Wang, Hao Zhu","doi":"10.1016/j.cmet.2024.05.015","DOIUrl":null,"url":null,"abstract":"<p>Somatic mutations in non-malignant tissues are selected for because they confer increased clonal fitness. However, it is uncertain whether these clones can benefit organ health. Here, ultra-deep targeted sequencing of 150 liver samples from 30 chronic liver disease patients revealed recurrent somatic mutations. <em>PKD1</em> mutations were observed in 30% of patients, whereas they were only detected in 1.3% of hepatocellular carcinomas (HCCs). To interrogate tumor suppressor functionality, we perturbed <em>PKD1</em> in two HCC cell lines and six <em>in vivo</em> models, in some cases showing that <em>PKD1</em> loss protected against HCC, but in most cases showing no impact. However, <em>Pkd1</em> haploinsufficiency accelerated regeneration after partial hepatectomy. We tested <em>Pkd1</em> in fatty liver disease, showing that <em>Pkd1</em> loss was protective against steatosis and glucose intolerance. Mechanistically, <em>Pkd1</em> loss selectively increased mTOR signaling without SREBP-1c activation. In summary, <em>PKD1</em> mutations exert adaptive functionality on the organ level without increasing transformation risk.</p>","PeriodicalId":9840,"journal":{"name":"Cell metabolism","volume":"43 1","pages":""},"PeriodicalIF":27.7000,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PKD1 mutant clones within cirrhotic livers inhibit steatohepatitis without promoting cancer\",\"authors\":\"Min Zhu, Yunguan Wang, Tianshi Lu, Jason Guo, Lin Li, Meng-Hsiung Hsieh, Purva Gopal, Yi Han, Naoto Fujiwara, Darren P. Wallace, Alan S.L. Yu, Xiangyi Fang, Crystal Ransom, Sara Verschleisser, David Hsiehchen, Yujin Hoshida, Amit G. Singal, Adam Yopp, Tao Wang, Hao Zhu\",\"doi\":\"10.1016/j.cmet.2024.05.015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Somatic mutations in non-malignant tissues are selected for because they confer increased clonal fitness. However, it is uncertain whether these clones can benefit organ health. Here, ultra-deep targeted sequencing of 150 liver samples from 30 chronic liver disease patients revealed recurrent somatic mutations. <em>PKD1</em> mutations were observed in 30% of patients, whereas they were only detected in 1.3% of hepatocellular carcinomas (HCCs). To interrogate tumor suppressor functionality, we perturbed <em>PKD1</em> in two HCC cell lines and six <em>in vivo</em> models, in some cases showing that <em>PKD1</em> loss protected against HCC, but in most cases showing no impact. However, <em>Pkd1</em> haploinsufficiency accelerated regeneration after partial hepatectomy. We tested <em>Pkd1</em> in fatty liver disease, showing that <em>Pkd1</em> loss was protective against steatosis and glucose intolerance. Mechanistically, <em>Pkd1</em> loss selectively increased mTOR signaling without SREBP-1c activation. In summary, <em>PKD1</em> mutations exert adaptive functionality on the organ level without increasing transformation risk.</p>\",\"PeriodicalId\":9840,\"journal\":{\"name\":\"Cell metabolism\",\"volume\":\"43 1\",\"pages\":\"\"},\"PeriodicalIF\":27.7000,\"publicationDate\":\"2024-06-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell metabolism\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cmet.2024.05.015\",\"RegionNum\":1,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell metabolism","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/j.cmet.2024.05.015","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

非恶性组织中的体细胞突变是经过选择的,因为它们能提高克隆的适应性。然而,目前还不确定这些克隆是否有益于器官健康。在这里,对30名慢性肝病患者的150份肝脏样本进行的超深度靶向测序发现了复发性体细胞突变。在30%的患者中观察到了PKD1突变,而在1.3%的肝细胞癌(HCC)中只检测到了PKD1突变。为了研究肿瘤抑制因子的功能,我们在两种 HCC 细胞系和六种体内模型中扰乱了 PKD1。然而,Pkd1单倍体缺失会加速部分肝切除术后的再生。我们对脂肪肝中的 Pkd1 进行了测试,结果表明 Pkd1 缺失对脂肪变性和葡萄糖不耐受有保护作用。从机理上讲,Pkd1缺失可选择性地增加mTOR信号传导,而不激活SREBP-1c。总之,PKD1突变在器官水平上发挥了适应性功能,而不会增加转化风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

PKD1 mutant clones within cirrhotic livers inhibit steatohepatitis without promoting cancer

PKD1 mutant clones within cirrhotic livers inhibit steatohepatitis without promoting cancer

Somatic mutations in non-malignant tissues are selected for because they confer increased clonal fitness. However, it is uncertain whether these clones can benefit organ health. Here, ultra-deep targeted sequencing of 150 liver samples from 30 chronic liver disease patients revealed recurrent somatic mutations. PKD1 mutations were observed in 30% of patients, whereas they were only detected in 1.3% of hepatocellular carcinomas (HCCs). To interrogate tumor suppressor functionality, we perturbed PKD1 in two HCC cell lines and six in vivo models, in some cases showing that PKD1 loss protected against HCC, but in most cases showing no impact. However, Pkd1 haploinsufficiency accelerated regeneration after partial hepatectomy. We tested Pkd1 in fatty liver disease, showing that Pkd1 loss was protective against steatosis and glucose intolerance. Mechanistically, Pkd1 loss selectively increased mTOR signaling without SREBP-1c activation. In summary, PKD1 mutations exert adaptive functionality on the organ level without increasing transformation risk.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cell metabolism
Cell metabolism 生物-内分泌学与代谢
CiteScore
48.60
自引率
1.40%
发文量
173
审稿时长
2.5 months
期刊介绍: Cell Metabolism is a top research journal established in 2005 that focuses on publishing original and impactful papers in the field of metabolic research.It covers a wide range of topics including diabetes, obesity, cardiovascular biology, aging and stress responses, circadian biology, and many others. Cell Metabolism aims to contribute to the advancement of metabolic research by providing a platform for the publication and dissemination of high-quality research and thought-provoking articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信